enrollees were positive for influenza. Of these, 143 (88%) were influenza A, including 71 pH1N1 cases (50%). Twenty-six pH1N1 cases were enrolled in the 2013-2014 influenza season. The age of pH1N1 cases was higher in the current season compared to the previous four seasons (median 35y vs 27.6y, respectively; P < 0.01). Cases in 2013-2014 had lower severity of cough (median score 2 vs 3; P = 0.04) and composite systemic symptom score (mean score of chills, muscle, headache, fatigue, and dizziness; median 1 vs 1.6; P = 0.01) than cases from the previous four years. The proportion of pH1N1 cases receiving pH1N1-containing vaccine in the season of enrollment varied from 22.2% in 2009 -2010 to 73.1% in 2013 -2014 . In 2013 -2014 (66%) of 29 pH1N1 cases had received seasonal influenza vaccine >14 days prior to illness: 8 (42%) received quadrivalent and 11 (58%) received trivalent vaccine. Quadrivalent vaccine recipients were younger than trivalent vaccine recipients (mean 29.1y vs 44.3y; P = 0.004), with similar doses of influenza vaccine received in the past 5 years. No significant differences in clinical severity were observed in the two vaccination groups.
Conclusion. Middle-aged adults were more affected during the resurgence of pH1N1 in 2013-14, while the highest incidence of pH1N1 2009-10 was among those <25y. Symptom severity of pH1N1 infection appears to have lessened over time.
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